93 related articles for article (PubMed ID: 9363912)
1. Protection against verocytotoxin in mice induced by liposome-coupled verocytotoxin.
Naito S; Horino A; Komiya T; Fukuda Y; Takahashi M; Ami Y; Suzaki Y; Satoh S; Gondaira F; Sugiyama J; Nakano Y; Mori M; Awai K; Nishinohara S; Komuro K; Uchida T
Int Arch Allergy Immunol; 1997 Nov; 114(3):293-7. PubMed ID: 9363912
[TBL] [Abstract][Full Text] [Related]
2. Induction of protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 in mice by shiga-like toxin-liposome conjugate.
Fukuda T; Kimiya T; Takahashi M; Arakawa Y; Ami Y; Suzaki Y; Naito S; Horino A; Nagata N; Satoh S; Gondaira F; Sugiyama J; Nakano Y; Mori M; Nishinohara S; Komuro K; Uchida T
Int Arch Allergy Immunol; 1998 Aug; 116(4):313-7. PubMed ID: 9693282
[TBL] [Abstract][Full Text] [Related]
3. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.
Bielaszewska M; Clarke I; Karmali MA; Petric M
Infect Immun; 1997 Jul; 65(7):2509-16. PubMed ID: 9199412
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice.
Kuribayashi T; Seita T; Fukuyama M; Furuhata K; Honda M; Matsumoto M; Seguchi H; Yamamoto S
J Infect Chemother; 2006 Oct; 12(5):251-6. PubMed ID: 17109087
[TBL] [Abstract][Full Text] [Related]
5. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7.
Padhye VV; Zhao T; Doyle MP
J Med Microbiol; 1989 Nov; 30(3):219-26. PubMed ID: 2479749
[TBL] [Abstract][Full Text] [Related]
6. Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid.
Ludwig K; Karmali MA; Smith CR; Petric M
Can J Microbiol; 2002 Jan; 48(1):99-103. PubMed ID: 11888169
[TBL] [Abstract][Full Text] [Related]
7. Protection of monkeys against Shiga toxin induced by Shiga toxin-liposome conjugates.
Suzaki Y; Ami Y; Nagata N; Naito S; Kato H; Taneichi M; Takahashi M; Komiya T; Satoh S; Gondaira F; Sugiyama J; Nakano Y; Mori M; Komuro K; Uchida T
Int Arch Allergy Immunol; 2002 Apr; 127(4):294-8. PubMed ID: 12021548
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1.
Karmali MA; Petric M; Winkler M; Bielaszewska M; Brunton J; van de Kar N; Morooka T; Nair GB; Richardson SE; Arbus GS
J Clin Microbiol; 1994 Jun; 32(6):1457-63. PubMed ID: 8077389
[TBL] [Abstract][Full Text] [Related]
9. Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.
Bitzan M; Klemt M; Steffens R; Müller-Wiefel DE
Infection; 1993; 21(3):140-5. PubMed ID: 8365810
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli.
Karmali MA; Petric M; Bielaszewska M
J Clin Microbiol; 1999 Feb; 37(2):396-9. PubMed ID: 9889226
[TBL] [Abstract][Full Text] [Related]
11. Ovalbumin-liposome conjugate induces IgG but not IgE antibody production.
Naito S; Horino A; Nakayama M; Nakano Y; Nagai T; Mizuguchi J; Komuro K; Uchida T
Int Arch Allergy Immunol; 1996 Mar; 109(3):223-8. PubMed ID: 8620090
[TBL] [Abstract][Full Text] [Related]
12. Ability of human sera to neutralise the activity of Vero cytotoxins VT1, VT2 and variant forms of VT2.
Scotland SM; Said B; Thomas A; Rowe B
FEMS Microbiol Lett; 1994 Jan; 115(2-3):285-9. PubMed ID: 8138140
[TBL] [Abstract][Full Text] [Related]
13. Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2.
Chart H; Law D; Rowe B; Acheson DW
J Clin Pathol; 1993 Nov; 46(11):1053-4. PubMed ID: 8254096
[TBL] [Abstract][Full Text] [Related]
14. Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1.
Boulanger J; Petric M; Lingwood C; Law H; Roscoe M; Karmali M
J Clin Microbiol; 1990 Dec; 28(12):2830-3. PubMed ID: 2280020
[TBL] [Abstract][Full Text] [Related]
15. Induction of protection against tetanus toxin in mice by tetanus toxoid-liposome conjugate.
Naito S; Horino A; Komiya T; Fukuda T; Takahashi M; Ami Y; Suzaki Y; Oka T; Okuma K; Morokuma M; Nakano Y; Mori M; Nishinohara S; Komuro K; Uchida T
Int Arch Allergy Immunol; 1998 Jul; 116(3):215-9. PubMed ID: 9693269
[TBL] [Abstract][Full Text] [Related]
16. Effect of verocytotoxins (Shiga-like toxins) on human neutrophils in vitro.
Holle JU; Williams JM; Harper L; Savage CO; Taylor CM
Pediatr Nephrol; 2005 Sep; 20(9):1237-44. PubMed ID: 15947986
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxin produced by Escherichia coli isolated from chickens with swollen head syndrome (SHS).
Parreira VR; Yano T
Vet Microbiol; 1998 May; 62(2):111-9. PubMed ID: 9695284
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.
Reymond D; Karmali MA; Clarke I; Winkler M; Petric M
J Clin Microbiol; 1997 Mar; 35(3):609-13. PubMed ID: 9041398
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of Escherichia coli phages encoding Vero cytotoxins: comparison of cloned sequences determining VT1 and VT2 and development of specific gene probes.
Willshaw GA; Smith HR; Scotland SM; Field AM; Rowe B
J Gen Microbiol; 1987 May; 133(5):1309-17. PubMed ID: 3655740
[TBL] [Abstract][Full Text] [Related]
20. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.
Rutjes NW; Binnington BA; Smith CR; Maloney MD; Lingwood CA
Kidney Int; 2002 Sep; 62(3):832-45. PubMed ID: 12164865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
